Cross-Sector entity
That works out to roughly 0.3 stories per week across a 165-day span. The busiest single day carried 4. Of the tracked stories, 3 of 7 also mention GSK, the most common co-covered peer. market-trends accounts for 3 of the 7 tracked stories, while 2 other categories carry the remainder.
7 verified stories tracked
Last mentioned: Aug 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
That works out to roughly 0.3 stories per week across a 165-day span. The busiest single day carried 4. Of the tracked stories, 3 of 7 also mention GSK, the most common co-covered peer. market-trends accounts for 3 of the 7 tracked stories, while 2 other categories carry the remainder. Negative sentiment appears in 0% of the tracked stories. We currently track 7 Cross-Sector stories that mention Collegium Pharmaceutical, published between February 26, 2026 and August 9, 2026. Each carries 3.4 original sources on average.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Collegium Pharmaceutical. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Wave and Collegium release full-year financial results and 2026 guidance.
Anticipated Filing
Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
RNA Editing Milestone
WVE-006 demonstrates successful RNA editing in AATD patients.
DMD Breakthrough
Wave reports industry-leading dystrophin expression for WVE-N531.
Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Source: dailypolitical.com · themarketsdaily.com
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
Source: manilatimes.net · manilatimes.net
